Business Wire

NJ-IFF

16.9.2019 17:02:06 CEST | Business Wire | Press release

Share
IFF Celebrates Opening of New Innovation Center in Holmdel’s Historic Bell Works

Regulatory News:

IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, nutrition and ingredients today opens the doors to its Home & Fabric Care Innovation Center at Bell Works in Holmdel, New Jersey. To mark the occasion, Chairman and CEO Andreas Fibig will be joined by business leaders, IFF employees, and Holmdel community members for a ribbon-cutting ceremony.

IFF’s Innovation Center is a 60,000 square-foot research and development hub with 32 state-of-the art evaluation spaces and labs. It is the new home for 120 IFF employees. Designed to foster co-creation and spark creativity, IFF’s space within Bell Works not only provides employees with collaborative areas and an office-wide open floor plan, but also draws inspiration from IFF’s newly launched purpose and brand identity.

IFF has a proud history of innovative firsts, and its opening in Holmdel connects the Company’s legacy with that of Bell Works, which is the home of so many breakthrough developments. The IFF Innovation Center today houses the Company’s foremost and cutting-edge fragrance technologies driving forward the future of fragrance for home care and fabric care, including digital olfaction technology, immersive virtual reality scent experiences, the latest generation of encapsulation technology, and industry-first scent printing.

Andreas Fibig, Chairman and CEO said: “Today’s opening at Bell Works is one of many steps we are taking to enable IFF’s vision for growth as a world-class, consumer-centered, integrated technology and research leader. Our new space provides us expanded capabilities and epitomizes IFF’s drive toward bold and unconventional thinking.”

Nicolas Mirzayantz, Divisional CEO, Scent, added: “Innovation runs through the DNA of Bell Works, making it the perfect environment to establish a new inspiring home for our creative teams as we seek to redefine and transform how we live in and care for the world. I look forward to IFF’s contributions to the story of this extraordinary place.”

Originally constructed between 1962 and 1964 and designed by world-renowned modernist architect Eero Saarinen, the building is revered for its role in spurring the development of some of the world’s foremost inventions and research concepts. In its 40-plus year history as the research headquarters for Bell Laboratories, Lucent and Alcatel-Lucent, the building housed a total of seven Nobel Prize winners, including those who conceived theories for the laser, the Big Bang theory, cellular technology, the transistor, and more.

Welcome to IFF

At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Klarna Names Chris Koegel as Chief Financial Officer12.11.2026 14:30:00 CET | Press release

Klarna Group plc (NYSE: KLAR), the everyday finance network, has appointed Chris Koegel as Chief Financial Officer, effective 1 January 2027, subject to regulatory approval. The appointment has been approved and endorsed by the Klarna Group plc board. He will succeed Niclas Neglén, who will remain CFO until the end of 2026. Koegel joins from Robinhood Markets Inc. (NASDAQ: HOOD), where he is Vice President, Head of Corporate Finance and Investor Relations. He joined Robinhood in 2022 and has served on the Leadership Team through a period of significant growth; the company’s valuation has grown from less than $10bn and has exceeded $100bn during his tenure. Before Robinhood, he was Head of Investor Relations at LPL Financial LLC (NASDAQ: LPLA) from 2015 to 2022, after spending 13 years at Bain & Company. Koegel has a BA in Mathematics from Williams College, an MBA from Dartmouth College, and is based in the US in the Boston, MA area. “Chris’s experience as a Finance leader at a US-liste

SLB Selected by Vår Energi for Integrated Drilling Services Offshore Norway12.11.2026 13:50:00 CET | Press release

Four-year scope covers two offshore rigs on the Norwegian Continental Shelf Global energy technology company SLB (NYSE: SLB) today announced it has been selected by Vår Energi as its main integrated drilling services supplier for the Transocean Barents and Deepsea Bergen rigs on the Norwegian Continental Shelf. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111105994/en/ SLB (NYSE: SLB) has been selected by Vår Energi as its main integrated drilling services supplier for the Transocean Barents and Deepsea Bergen rigs on the Norwegian Continental Shelf. The selection covers an initial four-year period, with four additional one-year extension options that could extend the scope through 2034. Two harsh-environment semisubmersibles will continuously drill exploration and development wells during this period. The integrated delivery model brings together technical expertise, digital workflows and operational execution across t

Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States12.11.2026 13:35:00 CET | Press release

Adults Living with NT1 Can Now be Prescribed ORZEYFUL, a New First-in-Class Orexin Medicine that Treats the Disease Holistically ORZEYFUL has the Potential to Redefine the Standard of Care by Targeting the Underlying Orexin Deficiency Associated with NT1 Takeda (TSE:4502/NYSE:TAK) announced that ORZEYFUL™ (oveporexton) CIV is now available in the U.S. by prescription for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults, bringing the first and only orexin agonist to this community. Learn more at ORZEYFUL.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111123458/en/ Orzeyful Logo “Living with narcolepsy type 1 is an ongoing struggle to keep it together – from scheduling naps and anticipating sleep attacks to figuring out how to be present as a mom and a professional,” said Emily P., clinical trial participant with NT1. “With ORZEYFUL, I feel more confident planning my day because my narcolep

MultiBank Group and Universal Sign Agreement to Develop USDU Settlement Capabilities for Institutional Clients12.11.2026 13:02:00 CET | Press release

MultiBank Group, one of the world’s largest financial derivatives institutions, has signed a memorandum of understanding (MoU) with Universal Digital Intl Limited (“Universal”) to develop settlement capabilities using USDU, Universal’s US dollar-backed stablecoin, for eligible institutional digital asset transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112192767/en/ MultiBank Group, one of the world’s largest financial derivatives institutions, has signed a memorandum of understanding (MoU) with Universal Digital Intl Limited (“Universal”) to develop settlement capabilities using USDU, Universal’s US dollar-backed stablecoin, for eligible institutional digital asset transactions. The initiative will begin with a pilot for eligible Professional Clients on mb.io, the Group’s cryptocurrency and digital asset trading platform. It combines MultiBank Group’s trading infrastructure, institutional relationships and li

IFF Launches CONCEPT MUSE, an AI-Powered Platform Designed to Accelerate Food and Beverage Product Development12.11.2026 13:00:00 CET | Press release

From inspiration to conceptualization, accelerated by technology and shaped by human expertise. IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences—today announced the launch of CONCEPT MUSE, a proprietary AI-powered tool for food and beverage concept generation. Drawing from IFF’s consumer insights, flavor expertise and market intelligence, CONCEPT MUSE helps identify market opportunities and uses simple prompts to generate differentiated concepts—complete with narratives, visual mockups and suggested technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111590865/en/ IFF's CONCEPT MUSE helps identify market opportunities and uses simple prompts to generate differentiated concepts. “Food and beverage innovation has always been a balance of art and science. Now digital transformation is adding a powerful new dimension to that equation,” said Benjamin Mattei, vice president of intellige

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye